India Pesticides gains EU approval for fungicide
India Pesticides secured Technical Equivalence approval from the European Union for its fungicide product on May 29, 2026. This regulatory approval is set to enhance the company's access to the European market, potentially increasing export revenues and foreign exchange earnings. The disclosure was made in compliance with SEBI regulations.

*this image is generated using AI for illustrative purposes only.
India Pesticides received Technical Equivalence (TEQ) approval in the European Union for a fungicide product on May 29, 2026. This regulatory milestone is expected to strengthen the company's export business by enhancing access to the European market. The approval is anticipated to contribute positively to export revenues and augment foreign exchange earnings.
The achievement marks a significant step in the company's global expansion strategy. By securing TEQ approval, India Pesticides can now market its fungicide product within the EU, catering to the international market segment.
Product Details
The approval specifics were disclosed in a filing submitted to the stock exchanges. The following table outlines the key details of the approved product:
| Particulars: | Description |
|---|---|
| Name of the Product: | Fungicide |
| Date of Approval: | 29-05-2026 |
| Category of the Product: | Pesticides |
| Market Catered: | International Market |
| Countries of Launch: | European Union |
The disclosure was made in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information is also available on the company's website.
Historical Stock Returns for India Pesticides
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.82% | +0.91% | -6.31% | -1.81% | -29.22% | -55.28% |
What is the expected timeline for the commercial launch of the fungicide in the EU?
How will this TEQ approval impact India Pesticides' overall revenue growth in the upcoming fiscal year?
Are there plans to seek similar regulatory approvals for other products in the company's portfolio?


































